Creative Biolabs is a pioneer in biotechnology, offering custom saRNA synthesis tailored for a variety of research and therapeutic applications. With over a decade of expertise in RNA synthesis and modifications, our team ensures high-quality saRNA characterized by superior stability and translational efficiency. Self-amplifying RNA (saRNA) is pivotal in developing next-generation vaccines and gene therapies due to its ability to produce higher protein levels from smaller doses. Committed to advancing gene therapy innovations, we provide expert, reliable solutions for all scientific needs.
The potential for mRNA application in human health is huge. Nowadays, mRNA is widely employed as a popular vaccine technique in the prevention and treatment of a wide range of infectious and non-infectious disorders. Two RNA vaccine platforms are available: conventional mRNA encoding only the protein of interest and self-amplifying RNA (saRNA) that encodes both the protein of interest and replicase derived from specific virus strains. The replicase is composed of nonstructural proteins (nsP1-nsP4) that are encoded by replicons. As the key component, it enables the self-replication of a saRNA molecule and leads to high expression levels of proteins at low doses. Upon delivery, the replicase can generate numerous copies of saRNA followed by the production of a large amount of the target protein as shown in Fig 1.
Fig. 1 The production of proteins using mRNA and saRNA.1
The main advantages of saRNA include:
Creative Biolabs provides one-stop saRNA synthesis services. You only need to provide the gene name or sequence, and we will perform codon optimization, sequence design, gene synthesis, and subsequent mRNA synthesis and purification. Throughout the entire process from product design to delivery, professionals provide one-on-one timely communication to ensure that the mRNA is synthesized efficiently and quickly while meeting your needs. We can also provide design and optimization suggestions for specific applications based on customer needs, including optimized design of 5'UTR and 3'UTR, optimized design of poly A tail, and codon optimization tools. Modification of mRNA molecules to improve the activity of specific applications, according to different customers have different needs for mRNA projects, and provide a variety of purification processes to choose from, including column purification, Oligo dT purification, and dsRNA removal; rich QC options to meet the research needs of each stage. Please get in touch with us in time to learn more about saRNA.
A: We can synthesize saRNA at various scales, from microgram to gram quantities, suitable for both research and clinical applications.
A: We offer lipid nanoparticles, polymer-based vectors, and hybrid delivery systems to enhance saRNA stability and delivery efficiency.
A: saRNA's self-amplifying properties lead to prolonged antigen expression, eliciting a stronger and longer-lasting immune response.
A: We provide comprehensive support, including project consultation, design optimization, synthesis, and post-synthesis analysis.
A: Yes, saRNA can be designed to encode tumor antigens, stimulating a targeted immune response against cancer cells.
This article focuses on optimizing the synthesis of self-amplifying RNA (saRNA) through in vitro transcription (IVT) using a design of experiments (DoE) approach. The primary goal is to maximize RNA yield by adjusting various components, such as magnesium ions, nucleoside triphosphates (NTPs), and other additives. Key findings include the significant impact of magnesium ions on RNA yield and the higher efficiency of acetate ions compared to chloride ions. The study demonstrates that the optimized IVT conditions can produce high-quality saRNA in large quantities, suitable for research and potential clinical applications in vaccines and biotherapeutics.
Fig.2 A full three-level factorial DoE analysis of saRNA synthesis through IVT.2
Cat. No | Product Name | Promoter |
---|---|---|
CAT#: GTVCR-WQ001MR | IVTScrip™ pT7-mRNA-EGFP Vector | T7 |
CAT#: GTVCR-WQ002MR | IVTScrip™ pT7-VEE-mRNA-EGFP Vector | T7 |
CAT#: GTVCR-WQ003MR | IVTScrip™ pT7-VEE-mRNA-FLuc Vector | T7 |
CAT#: GTVCR-WQ87MR | IVTScrip™ pT7-VEE-mRNA-Anti-SELP, 42-89-glycoprotein Vector | T7 |
Cat. No | Product Name | Type |
---|---|---|
CAT#: GTTS-WQ001MR) | IVTScrip™ mRNA-EGFP (Cap 1, 30 nt-poly(A)) | Reporter Gene |
CAT#: GTTS-WK18036MR | IVTScrip™ mRNA-Human AIMP2, (Cap 1, Pseudo-UTP, 120 nt-poly(A)) | Enzyme mRNA |
(CAT#: GTTS-WQ004MR) | IVTScrip™ mRNA-Fluc (Cap 1, 30 nt-poly(A)) | Reporter Gene |
(CAT#: GTTS-WQ009MR) | IVTScrip™ mRNA-β gal (Cap 1, 30 nt-poly(A)) | Reporter Gene |
References